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Abstract
CD200 is a cell surface glycoprotein that functions through engaging CD200 receptor on cells of the myeloid lineage and
inhibits their functions. Expression of CD200 has been implicated in a variety of human cancer cells including melanoma
cells and has been thought to play a protumor role. To investigate the role of cancer cell expression of CD200 in tumor
formation and metastasis, we generated CD200-positive and CD200-negative B16 melanoma cells. Subcutaneous injection
of CD200-positive B16 melanoma cells inhibited tumor formation and growth in C57BL/6 mice but not in Rag1
2/2C57BL/6
mice. However, i.v. injection of CD200-positive B16 melanoma cells dramatically inhibited tumor foci formation in the lungs
of both C57BL/6 and Rag1
2/2C57BL6 mice. Flow cytometry analysis revealed higher expression of CD200R in Gr1
+ myeloid
cells in the lung than in peripheral myeloid cells. Depletion of Gr1
+ cells or stimulation of CD200R with an agonistic antibody
in vivo dramatically inhibited tumor foci formation in the lungs. In addition, treatment with tumor antigen specific CD4 or
CD8 T cells or their combination yielded a survival advantage for CD200 positive tumor bearing mice over mice bearing
CD200-negative tumors. Taken together, we have revealed a novel role for CD200-CD200R interaction in inhibiting tumor
formation and metastasis. Targeting CD200R may represent a novel approach for cancer immunotherapy.
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Introduction
CD200 (also known as OX-2) is a member of the Ig super family
of proteins. It contains two extracellular immunoglobulin domains
and a small 19aa intracellular domain with no known signaling
motifs [1]. CD200 is expressed in a variety of normal tissues
including the central nervous system [2], epithelium structures in
the thymus [3], retinas [4], hair follicles [5] and the lymphoid cells
including B lymphocytes and activated T cells [6]. Recent studies
have revealed that CD200 is also expressed in a variety of human
cancer cells including human melanoma [7], ovarian cancer [8],
myeloid leukemia cells [9] and malignant B cells [10].
CD200 is the ligand for a receptor, namely CD200R. The
expression pattern of mouse and human CD200R is similar, with
strong expression in macrophages, neutrophils and mast cells [11].
Triggering CD200R suppresses myeloid cell activity in vitro and
engagement of CD200R by CD200 inhibits their activation [12].
Unlike most of the Ig superfamily receptors, CD200R lacks ITIM
domains [13]. However, the 67 aa cytoplasmic tail contains 3
tyrosine residues and the third tyrosine residue is located within a
NPXY motif, which is phosphorylated upon ligation of the CD200
receptor [14]. This leads to the recruitment and phosphorylation
of Dok-2 and 1, which then bind to RasGAP and SHIP
[14,15,16]. In macrophages and mast cells, this cascade has been
shown to inhibit the phosphorylation of ERK, P38 and JNK [15].
CD200 appears to limit autoimmune inflammation in animal
models of multiple sclerosis and arthritis [17] and lung injury
caused by viral infection [18], as CD200 deficient mice were found
to have a significantly increased disease severity due to hyper
activation of macrophages. CD200R-deficient mice were also
shown to be more susceptible to arthritis, presumably due to
enhanced functions of macrophages but not T cell responses [19].
These findings indicate that CD200-CD200R interactions are
involved in limiting the cellular functions of myeloid lineages of
cells.
Expression of CD200 has been found in multiple types of cancer
[9,10,20]. It is generally considered that expression of CD200 on
cancer cells has a protumor effect based on the following evidence.
First, in two correlation studies, CD200 mRNA expression in
malignant cells has been shown to be associated with decreased
survival of patients [9,10]; Second, CD200-expressing melanoma
and ovarian cancer cells downregulate Th1 cytokine production
when co-cultured with allogenic leukocytes [7,21] and anti-CD200
antibody treatment can enhance tumor rejection by peripheral
blood mononuclear cells in a hu-SCID adoptive transfer model
[22,23]; Third, in a recent study, CD200 expression was found to
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cell carcinoma [24]. While human correlation studies remain to be
confirmed in other cancer types, studies focusing on regulating
immune functions only focused on regulation of dendrtitic cells.
Our recent study [25] has revealed that tumor expression of
CD200 has a direct effect on tumor associated myeloid cells
(TAMCs).
Myeloid cells are obligate partners for tumor cell migration,
invasion and metastasis. Within the tumor microenvironment,
TAMCs facilitate angiogenesis and extracellular matrix break-
down, promote tumor cell migration and invasion, and suppress
antitumor immunity; at metastatic sites, TAMCs prepare the
target tissue for arrival of tumor cells [26,27]. Genetic ablation or
depletion of macrophages and inhibition of macrophage functions
have been shown to be effective in inhibiting tumor initiation and
growth [28,29,30]. Since TAMCs are the major lineages of cells
expressing CD200R [25], we hypothesize that tumor expression of
CD200 inhibits the functions of TAMCs and thereby affects tumor
formation and metastasis. To test this hypothesis, we have
generated CD200-positive and CD200-negative B16.F10.OVA
melanoma cells. Subcutaneous injection of CD200-positive B16
melanoma cells inhibited tumor formation and growth in C57BL/
6 mice but not in Rag1
2/2C57BL6 mice. However, i.v. injection
of CD200-positive B16 melanoma cells dramatically inhibited
tumor foci formation in the lungs of both C57BL/6 and Rag1
2/2
C57BL/6 mice. Depletion of Gr-1
+ cells and stimulation of
CD200R with an agonistic antibody in vivo inhibited tumor foci
formation in the lungs. In addition, treatment with tumor antigen
specific CD4 or CD8 T cells or their combination yielded a
significant improvement in survival of CD200 positive tumor
bearing mice. These data revealed a novel role for CD200-
CD200R interaction in inhibiting tumor formation and metastasis.
Materials and Methods
Ethic Statement
This study and experimental protocols were approved by The
Ohio State University Institutional Animal Care and Use
Committee (IACUC) with permit number 2008A0093-R1.
Mice
C57BL/6, Rag1
2/2 C57BL6, OT1 (transgenic mice with TCR
specific for H-2K
b: OVA 258–265) and OT2 (TCR transgenic
mice with TCR specific for I-A
b:OVA 323–339) mice were
purchased from Jackson laboratories. All mice were maintained
and cared for in OSU laboratory animal facilities which are fully
accredited by OSU IACUC.
Generation of CD200 positive and negative B16.OVA cells
B16.F10 melanoma cells expressing the full length chicken
ovalbumin (referred to as B16.OVA) has been described [31]. We
have cloned the full-length cDNA of mouse CD200 into pcDNA3
(Invitrogen) expression vector and used it to transfect B16.OVA
cells. The resulting hygromycin-resistant cells were selected for
CD200 expression using flow cytometry. The empty pcDNA3
expression vector was used to transfect B16.OVA cells to generate
B16.OVA.Ctrl cells. The generated CD200-positive or CD200-
negative cells were maintained in RPMI 1640 medium (Gibco)
supplemented with 5% FBS and 1% Penicillin/Streptomycin.
Real time PCR
Quantitative real-time PCR was performed using an ABI 7900-
HT sequence system (PE Applied Biosystems) with the QuantiTect
SYBR Green PCR kit (Qiagen) in accordance with the
manufacturer’s instructions. PCR was done using previously
determined conditions [32]. The following primers were used for
amplifying specific genes: chicken OVA: 59-ATC TCA AGC
TGT CCA TGC AG -39(forward) and 59-TGC GAT GTG CTT
GAT ACA GA -39 (reverse). The HPRT gene was simultaneously
amplified as endogenous control. The primers were 59-AGCC-
TAAGATGAGCGCAAGT-39 (forward) and 59-TTACTAGG-
CAGATGGCCACA-39 (reverse). Each sample was assayed in
triplicate and the experiments were repeated twice. The relative
amount of OVA mRNA was calculated by plotting the Ct (cycle
number) and the average relative expression for each group was
determined using the comparative method (2
2DDCt).
Establishment of subcutaneous and lung metastatic
tumors
To establish subcutaneous tumors in C57BL/6 and Rag1
2/2
mice, 1610
5 or 5610
5 cells/mouse were used for the subcutane-
ous injection. Development of tumors was monitored and tumors
were measured for length (a) and width (b) every three days using a
caliper. Tumor volumes were calculated as ab
2/2 [33]. To
establish tumor lung metastasis, each mouse was injected with
1610
5 B16.OVA.CD200 or B16.OVA.Ctrl cells via the tail vein.
Mice were monitored up to 3–4 weeks depending on symptoms
and treatments received. At the end of the experiments, mice were
sacrificed and lungs were collected, weighed and their tumor foci
counted.
Treatment of mice with established tumors
For T cell therapy of mice with established tumors, spleen and
lymph node cells of OT1 and/or OT2 mice were incubated with a
cocktail of antibodies (anti-CD4 mAb GK1.5 or anti-CD8 mAb
TIB210 and anti-FcR mAb 2.4G2). After removal of unbound
antibodies, the cells were incubated with anti-IgG coated magnetic
beads (Dynal Biotech). Antibody coated cells were then removed
using a magnet. The unbound cells consisted of .90% CD4 or
CD8 T cells. Purified CD4 (5610
6/mouse) or CD8 (5610
6/
mouse) or their combination (10610
6/mouse) were injected i.v.
into mice with established tumors.
For antibody treatment of mice with lung metastatic melanoma,
anti-CD200R mAb (OX110, Biolegend) or an isotype matched
control IgG mAb was injected into each mouse i.v. at a dose of
100 mg/mouse every 3 days, starting on day 0 for up to five times.
For depletion Gr1
+ cells in mice, each mouse was injected 250 mg
of anti-Gr1 antibody i.p. at 4 day intervals, starting on day 0.
Antibodies and flow cytometry
For CD200 and CD200R staining, PE-labeled anti-CD200
(clone OX-90) and FITC-labeled anti-CD200R (OX-110) anti-
bodies (Serotech) were used. FITC-, PE-, APC- or PercP- labeled
antibodies to CD4, CD8a, CD11b, Gr1, Va2, Vb5.1/5.2 and
isotype-matched control antibodies were purchased from BD
Biosciences. Cells were incubated with antibodies in 0.1 M PBS
(pH7.4) supplemented with 1% FCS and 0.1% sodium azide on
ice for 30 minutes. They were then washed three times and fixed
in 1% paraformaldehyde followed by flow cytometry analysis.
Isolation of CD11b
+ and Gr1
+ cells from spleens or lungs
Mononuclear cells were prepared from spleens and lungs of
C57BL/6 mice as described [34]. Briefly, minced mouse spleens
and lungs were digested in collagenase at 37uC for 90 min and
then filtered through a sterile nylon mesh. Myeloid cells were
isolated from spleens or lungs by first staining the cell suspensions
with PE-anti-CD11b mAb (BD biosciences) or PE-anti-Gr1 mAb
CD200 in Tumor Formation and Metastasis
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using anti-PE microbeads (Miltenyi Biotec). The isolated cells were
.90% pure. These cells were co-cultured with B16.OVA.Ctrl or
B16.OVA.CD200 cells (1:1 ratio), with or without LPS stimulation
(100 ng/ml). Culture supernatants were collected at 24 and
48 hours for cytokine analysis.
Cytokine ELISA
Standard ELISA procedures were used to detect IL-6, IL-10
and TNF-a in a variety of culture supernatants. All ELISA kits
were purchased from eBiosciences.
Statistical analysis
Student’s t test was used to compare tumor size and number
differences between two groups. For comparison of mice survival,
Kaplan-Myeier survival analysis and log-rank test were used
(version 10.0, SPSS, Inc., Chicago, IL). A p value less than 0.05
was considered significant.
Results
1. Expression of CD200 on melanoma cells inhibits tumor
formation and lung metastasis
Recent studies have revealed that CD200 is frequently expressed
on human melanoma cells. To test the significance of melanoma
expressed CD200 in tumor formation and metastasis, we generated
CD200-positive and CD200-negative B16 melanoma cells by
transfecting the B16.OVA cells with either the empty pCDNA3
expression vector or one carrying the murine CD200 cDNA. The
resulting cells were named as B16.OVA.CD200 and B16.OVA.Ctrl,
respectively. As shown in Figure 1A, B16.OVA.CD200 cells
expressed significant levels of CD200 while the control cells were
Figure 1. CD200 on melanoma cells inhibits tumor formation and lung metastasis. A. Flow cytometery analysis of B16.OVA.Ctrl and
B16.OVA.CD200 cells for CD200, MHC class I H2-K
b expression. qRT-PCR was used to examine OVA gene expression. B. 1610
5 of B16.OVA.Ctrl or
B16.OVA.CD200 cells were injected into each mouse subcutaneously. The tumor growth was observed over time. C. Kaplan-Meier survival analysis
and log-rank test were used to analyze mice survival. Mice with a tumor burden of 1.561.5 cm were sacrificed and counted as dead. Data shown in B
and C represent two experiments with similar results. D. C57BL/6 mice were given 1610
5 B16.OVA.Ctrl or B16.OVA.CD200 cells per mouse via their
tail vein. 20 days later mice were sacrificed and tumor growth in the lungs were shown. E. Average number of tumor foci in the lungs from each
group of mice shown in D. Error bars represent Mean 6 SEM. Student’s two-tailed t test was used for the statistical analysis. F. Average weight of
lungs from each group of mice shown in D. Data shown in D–F represent two experiments with similar results.
doi:10.1371/journal.pone.0031442.g001
CD200 in Tumor Formation and Metastasis
PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e31442CD200 negative. Both cell types also had similar levels of MHC
class I (H-2K
b)e x p r e s s i o n( Figure 1A, middle panel) and similar
levels of OVA gene expression (Figure 1A, lower panel). To
examine the impact of CD200 expression on tumor formation
and growth, we injected B16.OVA.CD200 or B16.OVA.Ctrl
cells into C57BL/6 mice subcutaneously (s.c.). As shown in
Figure 1B and Figure 1C, expression of CD200 significantly
inhibited tumor formation and growth, and promoted survival of
tumor bearing mice. Since B16.F10 tumors are highly metastatic
to the lung, we examined tumor growth in the lung metastasis
model. For this purpose, we injected C57BL/6 mice with 1610
5
of B16.OVA.CD200 or B16.OVA.Ctrl cells via their tail vein.
On day 20, we sacrificed all mice and extracted lungs from all
mice and compared their weight and tumor foci formation. As
demonstrated in Figure 1D, the lungs from mice who received
B16.OVA.Ctrl cells exhibited extensive formation of black foci,
characteristic of melanoma metastasis in the lungs. In contrast,
the lungs from mice injected with B16.OVA.CD200 cells had
much less melanoma foci, and the differences were highly
significant in terms of total foci numbers and total lung weight
(Figure 1E and Figure 1F). These results suggest that CD200
expression on melanoma cells significantly inhibit tumor
formation and lung metastasis.
2. Tumor expression of CD200 inhibits melanoma lung
metastasis through inhibition of Gr-1
+ myeloid cells
To understand if CD200-mediated inhibition of tumor
formation and metastasis observed in C57BL/6 mice were due
to stimulation of adaptive immunity, we did similar experiments in
Rag1
2/2 C57BL/6 mice. As demonstrated in Figure 2A and
Figure 2B, expression of CD200 on melanoma cells did not
significantly affect subcutaneous tumor formation and growth, and
it also did not significantly affect the survival of tumor bearing
mice. However, expression of CD200 on melanoma cells
dramatically affected tumor foci formation in the lungs. As
demonstrated in Figure 2C and Figure 2D, the lungs from mice
who received B16.OVA.CD200 cells had much less melanoma
foci compared with the lungs from mice that received
B16.OVA.Ctrl cells (Figure 2D). In addition, the weight of the
lungs and the survival times of mice were also significantly
different between the two groups of mice (Figure 2E and
Figure 2F). The results presented in Figure 1 and Figure 2
suggest that while adaptive immunity may play a role in the
subcutaneous tumor model, the difference in tumor lung
metastasis was mainly caused by innate immune components.
Since tumor expression of CD200 differentially affect tumor
formation in the subcutaneous model versus the lung metastatic
Figure 2. CD200 expression on tumor cells inhibits tumor lung metastasis in Rag1
2/2 C57BL6 mice. A. 1610
5 of B16.OVA.Ctrl or
B16.OVA.CD200 cells were injected into each Rag1
2/2 C57BL6 mouse s.c. The tumor growth was observed over time. B. Kaplan-Meier survival
analysis and log-rank test were used to analyze mice survival. Mice with a tumor burden of 1.561.5 cm were sacrificed and counted as dead. Data
shown in A and B represent two experiments with similar results. C. Rag
2/2 C57BL6 mice were given 1610
5 B16.OVA.Ctrl or B16.OVA.CD200 cells per
mouse via their tail vein. 20 days later mice were sacrificed and tumor lung metastasis was shown. D. Number of tumor foci in the lungs from mice
shown in C were quantified. Error bars represent 6 SEM. Student’s two-tailed t test was used for the statistical analysis. E. Average weight of lungs
from each group of mice shown in C. Error bars represent 6 SEM. Student’s two-tailed t test was used for the statistical analysis. F. Kaplan-Meier
survival curve of mice who received i.v. injection of B16.OVA.Ctrl or B16.OVA.CD200 cells. Data shown in C-F represents two experiments with similar
results.
doi:10.1371/journal.pone.0031442.g002
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microenvironment decided the differential susceptibility to
CD200-mediated suppression of tumor growth. During tumor
initiation, subcutaneous tumors mainly attract myeloid cells from
blood, while in the lung, high numbers of local myeloid cells exist.
We therefore compared splenic myeloid cells and those from the
lungs for the expressionof CD200R. As shown in Figure 3A, in the
lung and spleens of mice, we found three populations of myeloid
cells in each organ: CD11b
hiGr1
hi, CD11b
hiGr1
lo and
CD11b
loGr1
2 cells. In the lungs, CD11b
hiGr1
hi and CD11b
hiGr1
lo
cells are the cells that express high levels of CD200R, while
CD200R expression on CD11b
loGr-1
2 cells were low. In the
spleens, CD11b
hiGr1
lo cells expressed lower levels of CD200R,
while the other two populations of cells were essentially CD200R
negative. Thus, only one minor subset of systemic myeloid cells
express low levels of CD200R, while two subsets of Gr1
+ lung
myeloid cells express high levels of CD200R.
Since CD200R-positive cells also co-expressed Gr1, we tested if
depletion of Gr1 positive cells could affect melanoma lung
metastasis. We injected two groups of Rag1
2/2 mice with
B16.OVA.Ctrl tumor cells i.v. at a dose of 1610
5/mouse. One
group of the mice were treated with anti-mouse Gr1 mAb i.v.
every 4 days to deplete the Gr1
+ cells. Another group of mice were
treated with an isotype-matched control mAb. In parallel, a third
group of mice received B16.OVA.CD200 tumor cells i.v. at a dose
of 1610
5/mouse without mAb treatment. As demonstrated in
Figure 3B–D, anti-Gr1 treatment dramatically reduced tumor
foci in the lungs of mice that received B16.OVA.Ctrl cells. The
lung weight and number of tumor foci in the lungs of anti-Gr1
treated mice were similar to the mice that only received
B16.OVA.CD200. To determine if anti-Gr-1 treatment deleted
CD200R-positive myeloid cells, we analyzed lung mononuclear
cells isolated from anti-Gr-1 treated and control antibody treated
mice. As shown in Figure 3E, anti-Gr-1 treatment mainly deleted
a large population of Gr-1
hiCD11b
+ cells, which were also Ly6G
+
and CD200R
+. This result suggests that depletion of CD200R-
positive myeloid cells has similar effects to tumor expression of
CD200 in inhibiting melanoma tumor metastasis to the lungs.
Figure 3. Gr1
+ myeloid cells express CD200R and mediate lung metastasis. A. Flow cytometry analysis of CD200R expression in
mononuclear cells from spleens and lungs. Cells were prepared from spleen and lung of normal C57BL/6 mice and were stained for CD11b, Gr1 and
CD200R. The experiment was confirmed in three independent experiments with similar results. B. Two groups of C57BL/6 mice were injected with
B16.OVA.Ctrl cells (1610
5 cells/mouse) via their tail vein. Mice were treated with either 250 mg/mouse of anti-Gr-1 (RB6-8C5, BioXcell) or an isotype-
matched control antibody (anti-KLH, BioXcell). An untreated group of mice that received 1610
5/mouse of B16.OVA.CD200 cells were used for the
comparison. 21 days after tumor cell injection, tumor lung metastasis was examined. C. Lung weight in groups of mice shown in B. Error bars
represent 6 SEM. Student’s two-tailed t test was used for the statistical analysis. D. Average number of tumor foci in the lungs from each group of
mice shown in B. Error bars represent 6 SEM. Student’s two-tailed t test was used for the statistical analysis. E. Flow cytometry analysis of lung
mononuclear cells from anti-Gr-1 treated and control antibody treated mice. C57BL6 mice received either anti-Gr-1 (250 mg63 doses per mouse) or
isotype-matched control antibody i.p. Data shown represent three experiments with similar results.
doi:10.1371/journal.pone.0031442.g003
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the functions of Gr1
+ myeloid cells, we purified Gr1
+ cells from
spleens or lungs using MACS beads. We co-cultured purified
splenic and lung Gr1
+ cells with either B16.OVA.Ctrl or
B16.OVA.CD200 cells in the presence of LPS. The concentra-
tions of IL-6, IL-10 and TNF-a in the culture supernatants were
measured using ELISA. As shown in Figure 4, cytokine levels
were consistently lower in cultures containing CD200-positive
tumor cells, while CD200 blockade using an anti-CD200 antibody
abrogated the suppression of cytokine production (Figure 4, right
panel). These data suggest that tumor expression of CD200 can
directly inhibit the functions of Gr1
+ myeloid cells via interaction
with CD200R.
3. Triggering CD200R inhibits tumor foci formation in the
lungs
Our results suggest that CD200-CD200R interaction plays
important roles in both innate and adaptive components in tumor
immunity, therefore targeting CD200-CD200R interaction should
provide a potential option for treatment of cancer. CD200 is only
expressed in some lineage of tumors, while CD200R is expressed
in tumor associated myeloid cells essentially in all solid tumors;
thus, targeting CD200R should have broader implication in the
treatment of cancer. To test this hypothesis, we tested the efficacy
of an agonistic anti-CD200R mAb (OX110) [11] in the treatment
of lung metastasis of CD200-negative melanoma. To test the
efficacy of OX110 on myeloid cells, we isolated CD11b
+ cells from
Figure 4. Tumor expression of CD200 inhibits the functions of Gr1
+ myeloid cells. Gr1
+ cells were isolated from spleens and lungs of
C57BL/6 mice. The cells were then co-cultured with tumor cells at a 1:1 ratio for 48 hours in the presence of 100 ng/ml of LPS (left panel) and 10 mg/
ml of anti-CD200 mAb or an IgG2a isotype control mAb (right panel). The supernatants were collected from the co-cultures and were examined for
the presence of IL-6, IL-10 and TNF-a. Experiments were repeated at least 3 times with similar results. Data shown are mean 6 SEM of 5 mice.
Student’s two-tailed t test was used for the statistical analysis.
doi:10.1371/journal.pone.0031442.g004
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2/2 C57BL/6 mice. The cells were stimulated with LPS in
the presence of OX110 (Biolegend) or an isotype-matched control
mAb (Biolegend). As shown in Figure 5A, anti-CD200R mAb
significantly diminished production of cytokines by CD11b
+
myeloid cells, suggesting that mAb OX110 can inhibits the
functions of myelid cells. To test its in vivo effects on tumor foci
formation and lung metastasis, C57BL/6 mice were injected with
1610
5 B16.OVA.Ctrl cells i.v. Starting from day 0, we treated
mice with 100 mg/mouse of OX110 mAb or 100 mg/mouse of an
isotype-matched control IgG i.v. every 3 days. As shown in
Figure 5B, anti-CD200R treatment dramatically reduced
melanoma tumor formation in the lungs compared to treatment
with the control antibody. Numbers of melanoma foci
(Figure 5C) and lung weights (Figure 5D) were also
significantly different between the two groups. Thus, triggering
CD200R inhibits tumor foci formation in the lungs and targeting
CD200R by a triggering mAb is feasible for the treatment of
CD200-negative tumors.
4. Tumor expression of CD200 improves the efficacy of T
cell adoptive transfer therapy
The differential effects of tumor expression of CD200 on
subcutaneous tumor growth in C57BL/6 mice versus Rag1
2/2
mice (Figures 1&2) suggest that CD200 expression on tumor
cells affects adaptive immunity. We previously demonstrated that
tumor expression of CD200 inhibits the functions of tumor
associated myeloid cells and permits better tumor eradication by
CTL [25]. To test if expression of CD200 on melanoma cells
could improve the susceptibility to T cell therapy, we injected
5610
5 of B16.OVA.Ctrl or B16.OVA.CD200 tumor cells into
each Rag
2/2C57BL/6 mouse subcutaneously. The mice were
either left untreated, or treated with 5610
6 CD8
+ T cells purified
Figure 5. Triggering CD200R using a mAb inhibits melanoma lung metastasis. A. CD11b
+ cells were isolated from the spleen of C57BL/6
mice and were stimulated with LPS (100 ng/ml) in the presence or absence of a monoclonal anti-mouse CD200R antibody (OX110). Supernatants
from the cultures were collected at 24 and 48 hours and concentrations of IL-6, IL-10 and TNF-a were examined using ELISA. Data shown represents
three independent experiments with similar results. Data shown are mean 6 SEM from groups of three mice. Student’s two-tailed t test was used for
the statistical analysis. B. 1610
5 B16.OVA.Ctrl cells were injected into each C57BL/6 mice via their tail vein. Mice were treated with either 100 mg/
mouse of anti-CD200R (n=5) or an isotype-matched control antibody (n=5) every 3 days starting from day 0. 18 days later mice were sacrificed and
melanoma lung metastasis was examined in antibody-treated mice or controls. Data shown represents two experiments with similar results. C.
Average number of tumor foci in the lungs from each group of mice. Error bars represent 6 SEM. Student’s two-tailed t test was used for the
statistical analysis. D. Average weights of lungs from each group of mice. Error bars represent 6 SEM. Student’s two-tailed t test was used for the
statistical analysis.
doi:10.1371/journal.pone.0031442.g005
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+ T cells from OT2 mice or their
combination. As shown in Figure 6, no significant difference was
observed between untreated CD200-positive and CD200-negative
tumors (Figure 6A). Adoptive transfer of OVA-specific CD8
(Figure 6B), CD4 (Figure 6C) or their combination (Figure 6D)
significantly improved the efficacy of T cell therapy on CD200-
positive, but not on CD200-negative tumors. The tumor volumes
(left panel) of T cell-treated CD200-positive tumors were
significantly smaller and the survival times of mice with CD200-
positive tumors were significantly longer compared to mice with
CD200-negtive tumors receiving the same T cell treatment (right
panel). Thus, expression of CD200 on melanoma cells improves
the efficacy of T cell therapy.
Discussion
Expression of CD200 has been implicated in a variety of human
cancer cells including melanoma cells [7] and has been reported to
play protumor effects via inhibiting tumor immunity [7,22,24].
However, using CD200-positive and CD200-negative melanoma
tumor models, we have revealed a novel role for CD200-CD200R
interaction in inhibiting tumor formation and metastasis, i.e.
tumor expression of CD200 inhibits tumor formation and
metastasis via inhibiting the functions of CD200R
+ myeloid cells.
As we showed in other tumor models [25], we further confirm here
that CD200-positive melanoma tumors are more susceptible to
antigen specific T cell therapy compared to CD200-negative
melanoma. Thus, our data challenge the current paradigm that
Figure 6. CD200-positive tumors are more susceptible to adoptive T cell therapy. A. 5610
5 of tumor cells were injected into each Rag1
2/2
C57BL6 mouse s.c. Tumor growth (left) and survival of mice (right) were monitored over time. N=5 mice per group and data shown represents two
experiments with similar results. B. 5610
5 of tumor cells were injected into each Rag1
2/2 C57BL/6 mouse s.c. Mice were then given 5610
6/mouse of
purified CD8
+ T cells from OT1 mice i.v. 5 days after tumor cell injection. Five mice per group were used and data shown represents two experiments
with similar results. C. 5610
5 of tumor cells were injected into each Rag1
2/2 C57BL/6 mouse s.c. Mice were then given 5610
6/mouse of purified CD4
+
T cells from OT2 mice i.v. 5 days after tumor cell injection. Five mice per group were used and data shown represents two experiments with similar
results. D. 5610
5 of tumor cells were injected into each Rag1
2/2 C57BL/6 mouse s.c. Mice were then given 5610
6/mouse of purified OT1 and 5610
6/
mouse of purified OT2 T cells i.v. 5 days after tumor cell injection. Five mice per group were used.
doi:10.1371/journal.pone.0031442.g006
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Myeloid cells are pivotal in tumor initiation, tumor mass
formation, tumor progression and metastasis [27]. In the tumor
initiation and formation stage, myeloid cells produce an array of
factors that promote tumor establishment. During the tumor
progression and metastasis stages, myeloid cells provide support
for developing tissues through their matrix remodeling capacities,
synthesis of growth and angiogenesis factors and capacity in
suppressing antitumor immunity. Genetic ablation, depletion of
myeloid cells or inhibition of myeloid cell functions have been
shown to be effective in inhibiting tumor establishment and tumor
progression [28,29,30,35]. It has been found that increased
number of myeloid cells is strongly associated with shortened
survival in patients with classic Hodgkin’s lymphoma [36]. We
have recently demonstrated that tumor associated myeloid cells
express high levels of CD200R, and they are susceptible to
CD200-mediated inhibition [25]. In this study, we have compiled
evidence that tumor expressed CD200 can directly interact with
myeloid cells to inhibit tumor formation and metastasis in a
CD200R-dependent manner. In in vitro cultures, CD200-positive
tumor cells but not CD200-negative tumor cells strongly suppress
cytokine production by myeloid cells. Compared to peripheral
myeloid cells, Gr1
+ lung myeloid cells express much higher levels
of CD200R. This correlated with profound inhibition of tumor
formation and metastasis of CD200
+ B16 melanoma in the lung
while the effect was diminished in the periphery (Figures 1 and
2). In contrast to our observation, CD200 induction on tumor cells
was recently shown to correlate with more tumor metastasis [24].
However, in that study it was unclear if expression of CD200 on
metastatic tumors was responsible for tumor metastasis. In our
current study, we have clearly shown that depletion of a large
population of CD200R
+ myeloid cells (Ly6G
+) using anti-Gr1
mAb achieved a similar effect to CD200 expression on melanoma
cells (Figure 3). We also demonstrated that injection of a
triggering CD200R mAb dramatically inhibited tumor formation
and the metastatic ability of melanoma cells to the lung. Thus, our
data establish that tumor expression of CD200 inhibits tumor
formation and metastasis via inhibiting CD200R
+ myeloid cells.
Our previous study [25] has revealed that CD200-positive
plasmacytoma J558 and mastocytoma P815 tumors are more
susceptible to CTL adoptive transfer therapy presumably due to a
more permissive tumor microenvironment. In this study we found
that adoptive transfer of antigen-specific T cells (both CD4 and
CD8) also significantly promoted survival of mice with CD200-
positive melanoma tumors over CD200-negative tumors. More-
over, significant growth delay of CD200-positive B16 tumors in
immune competent mice but not in immune-deficient Rag1
2/2
mice suggest that adaptive immunity is also stimulated by CD200-
positive tumors. These observations are controversial to the
current concept that tumor expression of CD200 inhibits DC,
thereby inhibiting activation of tumor antigen specific T cells [7].
In mice with established tumors, the major populations of
CD200R
+ cells are MDSC and TAMs. Since activation of T cells
does not require direct interaction of whole tumor cell with DC,
the concept must be tested in vivo in a definitive model. Our data
support a model that tumor expression of CD200 inhibits
CD200R
+ myeloid cells in the tumor microenvironment, which
renders the tumor microenvironment more permissive to T cells
and confers better tumor destruction.
Given the important roles of CD200-CD200R interaction in
regulating tumor associated myeloid cells and in inhibiting tumor
formation and metastasis, targeting CD200-CD200R interaction
should provide an option for the immunotherapy of human
cancer. Because of the restricted expression of CD200R to myeloid
cells and the importance of these cells in essentially all tumor types,
targeting CD200R should be an ideal option. Our successful
treatment of CD200-negative tumors using a triggering anti-
CD200R mAb proves that this approach is feasible.
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